Christopher D Gocke

List of Publications by Year
in descending order

92 papers	2,793 citations	182225 30 h-index	214428 50 g-index
93 all docs	93 docs citations	93 times ranked	5924 citing authors

#	Article	IF	Citations
1	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of Clinical Oncology, 2022, 40, 189-201.	0.8	79
2	Lynch syndrome caused by a novel deletion of the promoter and exons 1â€“13 of MLH1 gene. Cancer Genetics, 2022, 262-263, 91-94.	0.2	0
3	Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer. Cancer Research, 2022, 82, P2-08-15-P2-08-15.	0.4	0
4	Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets. Clinical Cancer Research, 2022, 28, 2361-2372.	3.2	2
5	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Human Pathology, 2022, 126, 63-76.	1.1	5
6	Feasibility of Cell-Free DNA Collection and Clonal Immunoglobulin Sequencing in South African Patients With HIV-Associated Lymphoma. JCO Global Oncology, 2021, 7, 611-621.	0.8	7
7	Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies. Journal of Molecular Diagnostics, 2021, 23, 467-483.	1.2	11
8	IDH1 and IDH2 Mutations in Colorectal Cancers. American Journal of Clinical Pathology, 2021, 156, 777-786.	0.4	12
9	Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers, 2021, 13, 3246.	1.7	5
10	Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens. Journal of Molecular Diagnostics, 2021, 23, 1343-1358.	1.2	12
11	Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers. American Journal of Clinical Pathology, 2021, , .	0.4	0
12	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. Clinical Chemistry, 2021, 67, 1524-1533.	1.5	1
13	Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma. Cancer Genetics, 2021, 258-259, 18-22.	0.2	1
14	Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease. Blood, 2021, 138, 4298-4298.	0.6	0
15	A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 300-306.	2.0	36
16	Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1038-1043.	0.9	3
17	FLT3 inhibitors added to induction therapy induce deeper remissions. Blood, 2020, 135, 75-78.	0.6	21
18	Cancer spectrum and outcomes in the Mendelian short telomere syndromes. Blood, 2020, 135, 1946-1956.	0.6	79

#	Article	IF	Citations
19	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. Molecular Diagnosis and Therapy, 2020, 24, 461-472.	1.6	3
20	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. Blood Cancer Journal, 2020, 10, 69.	2.8	37
21	Flow cytometric analysis of fine needle aspirates is affected by tumor subtype, but not by anatomic location nor technique. Diagnostic Cytopathology, 2020, 48, 538-546.	0.5	1
22	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Advances, 2020, 4, 2567-2576.	2.5	37
23	IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution. Cancer Medicine, 2020, 9, 4386-4394.	1.3	18
24	Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?. Human Pathology, 2020, 98, 120-128.	1.1	4
25	The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing. Blood Advances, 2020, 4, 1192-1196.	2.5	37
26	DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant. Blood, 2020, 136, 26-26.	0.6	5
27	Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. American Journal of Clinical Pathology, 2019, 152, 675-685.	0.4	2
28	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer, 2019, 19, 665.	1.1	42
29	The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia. American Journal of Hematology, 2019, 94, 1141-1148.	2.0	33
30	Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. American Journal of Clinical Pathology, 2019, 152, 570-581.	0.4	6
31	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	3.2	118
32	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clinical Cancer Research, 2019, 25, 5475-5484.	3.2	17
33	Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. Archives of Pathology and Laboratory Medicine, 2019, 143, 174-182.	1.2	15
34	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.4	75
35	Clinical validation of coexisting driver mutations in colorectal cancers. Human Pathology, 2019, 86, 12-20.	1.1	10
36	PD-L1 expression in inflammatory myofibroblastic tumors. Modern Pathology, 2018, 31, 1155-1163.	2.9	15

#	Article	IF	Citations
37	The absolute percent deviation of IGHV mutation rather than a 98% cutâ€•off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. British Journal of Haematology, 2018, 180, 7-8.	1.2	5
38	Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 131-135.	1.4	3
39	Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations. American Journal of Surgical Pathology, 2018, 42, 1166-1181.	2.1	98
40	A next-generation sequencingâ€“based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Advances, 2018, 2, 825-831.	2.5	107
41	The Evolution of Earned, Transparent, and Quantifiable Faculty Salary Compensation. Academic Pathology, 2018, 5, 2374289518777463.	0.7	11
42	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	1.6	0
43	Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7â€‰+â€‰3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia Research, 2018, 72, 92-95.	0.4	30
44	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	1.2	10
45	Detection of Chromosomal Translocation in Hematologic Malignancies by a Novel DNA-Based Looped Ligation Assay (LOLA). Clinical Chemistry, 2017, 63, 1278-1287.	1.5	2
46	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	1.2	41
47	Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 97-99.	0.2	3
48	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 379-386.	3.2	50
49	Managing the genomic revolution in cancer diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 175-194.	1.4	3
50	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget, 2017, 8, 96684-96696.	0.8	32
51	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. Oncotarget, 2016, 7, 45237-45248.	0.8	25
52	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using nextâ€generation sequencing. Cancer Cytopathology, 2016, 124, 744-753.	1.4	31
53	A Polycythemia VeraJAK2Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1495-1498.	2.3	12
54	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. American Journal of Clinical Pathology, 2016, 145, 696-702.	0.4	22

#	Article	IF	Citations
55	Mutational spectrum of intraepithelial neoplasia in pancreatic heterotopia. Human Pathology, 2016, 48, 117-121.	1.1	13
56	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia, 2016, 30, 1916-1920.	3.3	79
57	Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight, 2016, 1, .	2.3	111
58	Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived. PLoS ONE, 2016, 11, e0163559.	1.1	9
59	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica, 2015, 100, 1172-1179.	1.7	93
60	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1337-1346.	2.3	23
61	Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma. Convergent Science Physical Oncology, 2015, 1, 015001.	2.6	1
62	Utility of BRAF mutation detection in fineâ€needle aspiration biopsy samples read as â€œsuspicious for papillary thyroid carcinomaâ€• Head and Neck, 2015, 37, 1788-1793.	0.9	17
63	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer, 2015, 15, 779.	1.1	92
64	Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122.	2.0	26
65	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology, 2015, 28, 1390-1399.	2.9	53
66	Challenges Posed to Pathologists in the Detection of KRAS Mutations in Colorectal Cancers. Archives of Pathology and Laboratory Medicine, 2015, 139, 211-218.	1.2	35
67	Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?. Journal of Molecular Diagnostics, 2015, 17, 209-224.	1.2	176
68	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. American Journal of Clinical Pathology, 2015, 144, 620-628.	0.4	43
69	A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML. Molecular Diagnosis and Therapy, 2015, 19, 409-417.	1.6	8
70	Lymph node metastases of melanoma: challenges for BRAF mutation detection. Human Pathology, 2015, 46, 113-119.	1.1	16
71	Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget, 2015, 6, 42334-42344.	0.8	69
72	Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2014, 18, 587-593.	1.6	129

#	Article	IF	Citations
73	Microsatellite Instability Confounds Engraftment Analysis of Hematopoietic Stem-cell Transplantation. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 416-420.	0.6	13
74	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. Molecular Diagnosis and Therapy, 2014, 18, 409-418.	1.6	34
75	Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 856-866.	0.4	128
76	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1989-1995.	2.0	31
77	Haplotype Counting by Next-Generation Sequencing for Ultrasensitive Human DNA Detection. Journal of Molecular Diagnostics, 2014, 16, 495-503.	1.2	17
78	False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures. Journal of Molecular Diagnostics, 2014, 16, 541-549.	1.2	43
79	The Drowning Heart: An Ambiguous Lymphoma. American Journal of Medicine, 2014, 127, 817-819.	0.6	1
80	Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-Î± (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leukemia Research, 2014, 38, 886-890.	0.4	8
81	Tandem Duplication PCR. Diagnostic Molecular Pathology, 2013, 22, 149-155.	2.1	10
82	Pleural Fluid Cytology of the Polymorphous Variant of EBV-Positive Diffuse Large B-Cell Lymphoma: First Report and Distinction from a Reactive Process. Case Reports in Pathology, 2013, 2013, 1-4.	0.2	3
83	The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 132-137.	0.2	19
84	Î”-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations. Journal of Molecular Diagnostics, 2011, 13, 85-92.	1.2	17
85	Clonal immunoglobulin DNA in the plasma of patients with AIDS lymphoma. Blood, 2011, 117, 4860-4862.	0.6	8
86	Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 1873-1881.	0.6	17
87	A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2009, 11, 359-363.	1.2	35
88	Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood, 2009, 113, 5920-5926.	0.6	159
89	Response: Hodgkin lymphoma stem cells. Blood, 2009, 114, 3971-3972.	0.6	3
90	A Molecular Fraction Collecting Tool for the ABI 310 Automated Sequencer. Journal of Molecular Diagnostics, 2007, 9, 598-603.	1.2	9

#	Article	IF	Citations
91	Clonal Heavy and Light Chain Immunoglobulin DNA in Plasma/Serum of AIDS Lymphoma Patients.. Blood, 2007, 110, 1579-1579.	0.6	0
92	Novel Retinoic Acid Metabolism Blocking Agents (RAMBAs) Induce Differentiation in ATRA Resistant Cell Line: Potential New Theraputics for Acute Promyleocytic Leukemia (APL).. Blood, 2005, 106, 746-746.	0.6	10